Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and P...
Strong first quarter performance, with net sales1 of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) − Biosimila...
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab bios...
GUIDANCE 2024 For full-year 2024, the company expects net sales to grow mid-single digit in constant currencies versus prior y...
Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-ye...
-8-K
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761362
